TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: reduced proportion of participants choosing high-added sugar beverages
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: episodes and duration of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: episodes and duration of RTIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of parasite species in playgrounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in arterial line patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate (ORR) by week 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change of body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean change of weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change from baseline to day 28 in off time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in visual field testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: out-of-bed life behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to completion of oxygen administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days to achieve discharge criteria
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: ALSFRS-R points progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal adherence to adherence pattern A
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Anxiety levels (STAI scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain levels (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: six-minute walk test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of fluoride in biofilm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of regression of NVE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of persistence of NVD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrafraction motion greater than 5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MSIS-29 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major complications (Clavien-Dindo grade III or higher)
Endpoint domain: Adverse events/effects
Primary endpoint: PrEP disclosure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MVC for cervical extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: RTD for cervical extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MVPA in minutes per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute day-2 hematoma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: significant hematoma progression
Endpoint domain: Adverse events/effects
Primary endpoint: overall implant survivorship
Endpoint domain: Mortality/survival
Primary endpoint: Annual incidence of metachronous cancer
Endpoint domain: Mortality/survival
Primary endpoint: Curative resection rate of ESD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of leftover opioid disposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daytime eye rubbing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleeping position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aging male symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TC concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ApoB concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rebleeding after hemostasis
Endpoint domain: Adverse events/effects
Primary endpoint: Bleeding volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: VAS during rest and coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue analgesic requirement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Voice quality improvement (GRBAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Voice quality improvement (VRQOL)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Voice quality improvement (CAPE-V)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIT-6 total score improvement
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: onset of globe akinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of globe and lid akinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient and surgeon satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in confidence scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Survival to hospital discharge with favorable neurologic outcomes
Endpoint domain: Mortality/survival
Primary endpoint: gait stance phase duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kt/V improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-min walking distance increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement at 3-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the number of days without rescue medication use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of communication about sexuality and pregnancy prevention
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Perceived competence to prevent pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Median time to pain relief (TMPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiorenal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NRS‐11 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum VEGF‐C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum PGE2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprevalence of CE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUDIT change scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hypotensive events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-year Event-Free Survival (EFS)
Endpoint domain: Mortality/survival
Primary endpoint: requirement for rescue fentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitigation of excessive gestational weight gain (GWG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean 24-h post LPS BAL total protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AOBP sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUSCAN score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grip and pinch strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete wound healing at three weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA DSB level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vaccine interest
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: vaccine advocacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: vaccine uptake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in WMH volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) for predictive model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Very-low-density lipoprotein markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients achieving HbA1c <7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: commitment at T1
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: perceived increase in physical activity between T0 and T2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: active choice at T1
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: reverse tightening values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antihypertensive treatment intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain control during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IUA recurrence at second-look hysteroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ERR for major coronary events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ERR for ipsilateral lung tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Satisfaction among dermatology patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SAQ Summary score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Defocus curve performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective disturbance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy of secukinumab in moderate-to-severe psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of CRP and SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased need for respiratory interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in acute care visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: pain symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak eosinophil counts/hpf
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Endoscopic signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIQ score < 39 (mild functional impairment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No longer met FM criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: virological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: alanine aminotransferase normalization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: no progression of liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: trunk impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall FV intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with the waiting time
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: feeling of safety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rehabilitation motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: WS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of care implementation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: carer-reported self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PC reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement in HCV care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: field performance deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: social functioning improvement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Reduction in the Clinician ADHD-RS-IV total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: direct breastfeeding practice rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breastfeeding continuation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thinking, memory, learning, and concentration
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Schirmer’s test II wetting distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy in evaluation of lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Physicians' acceptance of health apps
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in knowledge about dementia
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Support received from home-care staff
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Treatment success at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiologic failure at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Complicated bacteremia at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: malignancy events
Endpoint domain: Adverse events/effects
Primary endpoint: Three-year recurrence-free survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: mortality hazard ratio for fluorouracil
Endpoint domain: Mortality/survival
Primary endpoint: mortality hazard ratio for erlotinib
Endpoint domain: Mortality/survival
Primary endpoint: respiratory-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Cognitive Improvement (CI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of grade 2 or greater cumulative peripheral neuropathy (PN)
Endpoint domain: Adverse events/effects
Primary endpoint: relative dose intensity (RDI) of oxaliplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative intravenous morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration to the first readmission
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients achieving none or mild glabellar line severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of effect of ≥24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the 1st stage of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of cesarean section (CS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: prebronchodilator spirometry consistent with COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: prevalence of emphysema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: inhaler use and respiratory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Parents satisfaction with diagnosis and treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Score of local skin reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Quality of care interactions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum RSV-neutralizing antibodies increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mild upper respiratory symptoms and/or fever
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative incision pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative throat pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h and nocturnal systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for analgesic supplementation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: achievement of age-appropriate educational milestones
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: emotion dysregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-harm
Endpoint domain: Adverse events/effects
Endpoint subdomain: null
Primary endpoint: Three-year invasive disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Grade ≥2 skin toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in fibrosis stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Vmin reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage reduction in lesion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate on 3D assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Habitual use of floss and mouthrinse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Biological effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean minimum SpO2 value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hypoxemic episodes (SpO2: ≤94%)
Endpoint domain: Adverse events/effects
Primary endpoint: Pain at its worst
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emerging childhood obesity at 36-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fecal butyrate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Unilateral Spatial Neglect (USN) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical ocular disease scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal leukocyte infiltrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular viral loads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in RVEF <20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in RVEF 20%-to-30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Upper limb disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: velocity at maximal oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage LDL-C change from baseline to Day 510
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time-adjusted change from baseline after Day 90 and up to Day 540
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial peak blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incremental Area Under the Curve (IAUC) for blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of pulmonary function tests (PFTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of oxidative stress and cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Completion rates of ASA24‐2016 recalls and DHQ‐II
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: pMDI inhalation techniques mistakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung functions (FEV1 and PEF% predicted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: asthma control test (ACT) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of severe OSA (AHI ≥ 30 events/h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes